跳至主要内容
临床试验/EUCTR2021-005043-71-NL
EUCTR2021-005043-71-NL进行中(未招募)1 期

A Phase 2, Comparative Randomised Trial to Evaluate the impact of reduced COVID-19 mRNA vaccination regimens on immunological responses and reactogenicity in paediatric subjects with and without prior SARS-CoV-2 infection - Immunogenicity and reactogenicity of reduced COVID-19 mRNA vaccination regimens in children (CoVacc)

niversity Medical Center Utrecht0 个研究点目标入组 400 人开始时间: 2021年10月9日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. 12 or 13 years of age on day of signing the informed consent form.
  • 2. In good health or stable clinical condition.
  • 3. Has reviewed the subject information and signed the informed consent form.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 400
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Has previously received any investigational or licensed COVID-19 vaccine.
  • 2. Has known congenital or acquired immune disorder or immunodeficiency that may interfere
  • with vaccine response e.g. known infection with human immunodeficiency virus (HIV) with
  • low CD4 count or other immunosuppression at time of signing informed consent form.
  • 3. Has a history of autoimmune disease or an active autoimmune disease requiring therapeutic
  • intervention (including systemic glucocorticoids), or findings that may have a significant
  • effect on the target endpoints and which may therefore mask or inhibit the therapeutic
  • effect under investigation as judged by the investigator.
  • 4. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion
  • of the investigator, contraindicate intramuscular injection.
  • 5. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction
  • (eg, anaphylaxis) to any component of the study intervention(s).
  • 6. Receipt of medications intended to prevent COVID-19.
  • 7. Uses drugs with significant interaction with the investigational product or has any
  • contraindications as per the Summary of Product Characteristics.
  • 8. Other medical or psychiatric condition or laboratory abnormality that may increase the risk
  • of study participation or, in the investigator’s judgment, make the participant inappropriate
  • for the study.
  • 9. Has any kind of dependency on the principal investigator or member of the study team or is
  • employed by the sponsor or principal investigator.
  • 10. Is unable to report solicited adverse events.

研究者

相似试验

进行中(未招募)
1 期
Clinical Study Evaluating the immune responses and safety of single versus two dose COVID-19 mRNA Vaccination in children (CoVacc)Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865
EUCTR2021-005043-71-DEniversity Medical Center Utrecht200
进行中(未招募)
1 期
Clinical Study Evaluating the immune responses and safety of single versus two dose COVID-19 mRNA Vaccination in children (CoVacc)Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2021-005043-71-NOniversity Medical Center Utrecht200
进行中(未招募)
1 期
Immunogenicity and reactogenicity of reduced COVID-19 vaccination regimen in children (CoVacc).Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865
EUCTR2021-005043-71-GRniversity Medical Center Utrecht200
进行中(未招募)
1 期
Clinical Study Evaluating the immune responses and safety of single versus two dose COVID-19 mRNA Vaccination in children (CoVacc)Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865
EUCTR2021-005043-71-SEniversity Medical Center Utrecht200
招募中
2 期
A Phase 2, Comparative Randomised Trial to Evaluate the impact of reduced COVID-19 mRNA vaccination regimen on immunological responses and reactogenicity in paediatric subjects with prior SARS-CoV-2 immunity
NL-OMON54453niversitair Medisch Centrum Utrecht50